Human Genome Science study shows safety of HGS-ETR1, GlaxoSmithKline to co-develop

By Angela McDaniels

Seattle, Nov. 1 - Human Genome Sciences Inc. said that the results of a phase-2 clinical trial demonstrate that HGS-ETR1 (mapatumumab) is well tolerated and can be administered safely in patients with advanced colorectal cancer.

The results were presented in Paris Tuesday at the European Cancer Conference in a poster entitled "Results of a Phase-2 Trial of HGS-ETR1 in Subjects with Relapsed or Refractory Colorectal Cancer."

In addition, GlaxoSmithKline has exercised its option under a June 1996 agreement to develop and commercialize HGS-ETR1 jointly with Human Genome Sciences, the latter said.

Under the terms of the agreement, the companies will share equally in phase-¾ development costs, sales and marketing expenses and profits of any product that is commercialized under the agreement.

Human Genome Sciences is a pharmaceutical company based in Rockville, Md., that develops drugs for unmet medical needs, with a primary focus on protein and antibody drugs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.